[{"orgOrder":0,"company":"Provention Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"","productType":"Vaccine","year":"2020","type":"Not Applicable","leadProduct":"PRV-101","moa":"","graph1":"Endocrinology","graph2":"IND Enabling","graph3":"Provention Bio","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"","sponsorNew":"Provention Bio \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Provention Bio \/ Not Applicable"},{"orgOrder":0,"company":"Cure Pharmaceutical","sponsor":"Axiom Capital Management","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"","productType":"Small molecule","year":"2020","type":"Financing","leadProduct":"Sildenafil Citrate","moa":"","graph1":"Endocrinology","graph2":"IND Enabling","graph3":"Cure Pharmaceutical","amount2":0.01,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Endocrinology","amount2New":0.01,"dosageForm":"Film","sponsorNew":"Cure Pharmaceutical \/ Axiom Capital Management","highestDevelopmentStatusID":"5","companyTruncated":"Cure Pharmaceutical \/ Axiom Capital Management"},{"orgOrder":0,"company":"Alnylam Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"ALN-KHK","moa":"","graph1":"Endocrinology","graph2":"IND Enabling","graph3":"Alnylam Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Alnylam Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Alnylam Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Vertex Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"","productType":"Cell and Gene therapy","year":"2023","type":"Not Applicable","leadProduct":"VX-264","moa":"","graph1":"Endocrinology","graph2":"IND Enabling","graph3":"Vertex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Implant","sponsorNew":"Vertex Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Vertex Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"SAB Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"SAB-142","moa":"","graph1":"Endocrinology","graph2":"IND Enabling","graph3":"SAB Biotherapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"","sponsorNew":"SAB Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"SAB Biotherapeutics \/ Not Applicable"}]

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Weekly News Recap
#Phispers

Stock Recap
#PipelineProspector

Check COS database
Check USDMF database

Contact Us
PharmaScopic.com

Filters

×

filter

Company Name

filter

Year

filter

DEALS // DEV.

filter

Country

filter

Sponsor

filter

Therapeutic Area

filter

Study Phase

filter

Deal Type

filter

Product Type

filter

Dosage Form

filter

Lead Product

filter

Target

All Developments

Therapeutic Area by Lead Product

Study Phase by Lead Product

Company by Lead Product

Top Deals by Deal Size (USD bn)

Reset All

01

Provention Bio

U.S.A

Pharmtech & Ingredients

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Lead Product(s) : PRV-101

Therapeutic Area : Endocrinology

Study Phase : IND Enabling

Sponsor : Not Applicable

Deal Size : Not Applicable

Deal Type : Not Applicable

Provention Bio and Vactech Announce Publication of Proof-of-Concept Data for a Preclinical Prototype of Coxsac...

Details : Publication results demonstrates that a preclinical prototype of Provention's polyvalent coxsackievirus B (CVB) vaccine, PRV-101, is well-tolerated, immunogenic and highly protective in relevant animal models.

Brand Name : Undisclosed

Molecule Type : Vaccine

Upfront Cash : Not Applicable

May 18, 2020

Lead Product(s) : PRV-101

Therapeutic Area : Endocrinology

Highest Development Status : IND Enabling

Sponsor : Not Applicable

Deal Size : Not Applicable

Deal Type : Not Applicable

Stock Recap
#PipelineProspector

Data Compilation
#PharmaFlow

02

SAB Biotherapeutics

U.S.A

Pharmtech & Ingredients

Not Confirmed

03

SAB Biotherapeutics

U.S.A

Pharmtech & Ingredients

Not Confirmed

04

Biomea Fusion

U.S.A

Pharmtech & Ingredients

Not Confirmed

05

SAB Biotherapeutics

U.S.A

Pharmtech & Ingredients

Not Confirmed

06

MBX Biosciences

U.S.A

Pharmtech & Ingredients

Not Confirmed

07

Vertex Pharmaceuticals

U.S.A

Pharmtech & Ingredients

Not Confirmed

08

SAB Biotherapeutics

U.S.A

Pharmtech & Ingredients

Not Confirmed

09

Alnylam Pharmaceuticals

U.S.A

Pharmtech & Ingredients

Not Confirmed

10

Biomea Fusion

U.S.A

Pharmtech & Ingredients

Not Confirmed

1
2